Clicky

Alligator Bioscience AB(ATORX)

Description: Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.


Keywords: Medicine Biotechnology Cancer Immunology Antibodies Immunotherapy Treatment Of Cancer Cancer Treatment Antibody Monoclonal Antibody Cancer Therapeutics Metastatic Cancer Treatment Of Metastatic Cancer Bispecific Antibody Cancer Novimmune Cd40 Research Based Biotechnology

Home Page: www.alligatorbioscience.se

Medicon Village
Lund, 223 81
Sweden
Phone: 46 4 65 40 82 00


Officers

Name Title
Mr. Søren Bregenholt Ph.D. Chief Exec. Officer
Dr. Malin Carlsson Head of R&D, Exec. VP & COO
Ms. Marie Svensson Chief Financial Officer
Dr. Peter Ellmark Ph.D. Chief Scientific Officer
Ms. Julie Silber Director of Communications & Investor Relations
Mr. Sumeet Ambarkhane M.D. Chief Medical Officer

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.5678
Price-to-Sales TTM: 17.7601
IPO Date:
Fiscal Year End: December
Full Time Employees: 55
Back to stocks